Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03669588 · ClinicalTrials.gov registry record · Phase 3
An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
A Phase 3 study of Generalized Myasthenia Gravis, sponsored by argenx.
- Completed
- Registry status
- Phase 3
- Development phase
- 167
- Enrollment target
- 20
- Study locations
NCT03669588 is a Phase 3 study of Generalized Myasthenia Gravis that has completed, run by argenx. The registered enrollment target is 167 participants, above the 125-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (34% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT03669588, a Phase 3 study of Generalized Myasthenia Gravis, has completed, sponsored by argenx.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 167 participants
- Enrollment target
- 20
- Study locations
Study Summary
A randomized, double-blind, placebo controlled, multicenter Phase 3 trial to evaluate the efficacy, safety, tolerability, quality of life and impact on normal daily activities of ARGX-113 in patients with gMG.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL ARGX-113
Study Locations (20)
California
- Investigator Site 66 - Carlsbad
- Investigator Site 5 - Los Angeles
- Investigator Site 49 - Los Angeles
- Investigator Site 18 - Orange
- Investigator Site 40 - Palo Alto
- Investigator Site 59 - San Francisco
Florida
- Investigator Site 34 - Jacksonville
- Investigator Site 4 - Tampa
Arizona
- Investigator Site 29 - Phoenix
Colorado
- Investigator Site 58 - Aurora
Illinois
- Investigator Site 30 - Springfield
Iowa
- Investigator Site 25 - Iowa City
Kansas
- Investigator Site 21 - Kansas City
Massachusetts
- Investigator Site 27 - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 167 participants |
| Start Date | 2018-08-22 |
| Est. Completion | 2020-04-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03669588
The ClinicalTrials.gov registry entry for NCT03669588 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 167 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 125-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (34% higher). The listed sponsor is argenx, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Generalized Myasthenia Gravis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03669588 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT03669588 about?
NCT03669588 is a clinical study titled "An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness". A randomized, double-blind, placebo controlled, multicenter Phase 3 trial to evaluate the efficacy, safety, tolerability, quality of life and impact on normal daily activities of ARGX-113 in patients with gMG.
What is the current status of trial NCT03669588?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 167 participants. The study started on 2018-08-22. Estimated completion is 2020-04-06.
What conditions does trial NCT03669588 study?
This clinical trial studies the following conditions: Generalized Myasthenia Gravis.
What interventions are being tested in trial NCT03669588?
The interventions under investigation include: Placebo (BIOLOGICAL), ARGX-113 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03669588?
This trial is sponsored by argenx, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03669588 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Generalized Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
RECRUITING · Phase 3
-
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.